Monoclonal Antibody Therapy against Acinetobacter baumannii,Infection and Immunity

当前位置： X-MOL 学术 › Infect. Immun. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Monoclonal Antibody Therapy against Acinetobacter baumannii
Infection and Immunity ( IF 2.9 ) Pub Date : 2021-07-26 , DOI: 10.1128/iai.00162-21
Travis B Nielsen _{1,

2,

3} , Jun Yan ₃ , Matthew Slarve ₃ , Peggy Lu ₃ , Rachel Li ₃ , Juan Ruiz ₃ , Bosul Lee ₃ , Elizabeth Burk ₃ , Yuli Talyansky ₃ , Peter Oelschlaeger ₄ , Kyle Hurth ₅ , William Win ₅ , Brian M Luna ₃ , Robert A Bonomo _{6,

7,

8} , Brad Spellberg ₉

Affiliation

Stritch School of Medicine, Loyola University Chicagogrid.164971.c, Maywood, Illinois, USA.
Parkinson School of Health Sciences and Public Health, Loyola University Chicagogrid.164971.c, Maywood, Illinois, USA.
Department of Molecular Microbiology & Immunology, Keck School of Medicine at the University of Southern Californiagrid.42505.36, Los Angeles, California, USA.
Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciencesgrid.268203.d, Pomona, California, USA.
Department of Pathology, Keck School of Medicine at the University of Southern Californiagrid.42505.36, Los Angeles, California, USA.
Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio, USA.
Los Angeles County and University of Southern Californiagrid.42505.36 Medical Center, Los Angeles, California, USA.

Background: Extremely drug-resistant (XDR) Acinetobacter baumannii is a notorious and frequently encountered pathogen demanding novel therapeutic interventions. An initial monoclonal antibody (MAb), C8, raised against A. baumannii capsule proved a highly ...

中文翻译：